Current Headlines

  1. Quantum Biopharma Announces Signing Of An Agreement With A Global Pharmaceutical Contract Research Organization To Prepare An IND (Investigational New Drug) Application Package For Lucid-21-302 (Lucid-MS), A First-In-Class Treatment For Multiple Sclerosis 5/20/2025

    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA.

  2. Candidate Drug That Boosts Protective Brain Protein In Mice Has Potential To Treat Alzheimer's Disease 5/20/2025

    As researchers work to improve treatment of Alzheimer’s disease, new research by UCLA Health identified a candidate drug that reduces levels of a toxic form of a protein in the brain caused by the disease and improved memory in mice by boosting production of a protective protein.

  3. Scientists Discover Potential New Targets For Alzheimer's Drugs 5/20/2025

    By combining information from many large datasets, MIT researchers have identified several new potential targets for treating or preventing Alzheimer’s disease.

  4. Honorhealth Research Institute Patient With Advanced Skin Cancer In Remission For More Than A Year Following Clinical Trial Of Werewolf Therapeutics' Investigational Novel Conditionally Activated IL-2 Pro-Drug WTX-124 5/20/2025

    A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with a new targeted immune-therapy in a clinical trial at HonorHealth Research Institute.

  5. Pfizer Enters Into Exclusive Licensing Agreement With 3SBio 5/19/2025

    Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors.

  6. Rani Therapeutics Announces Research Agreement With Chugai 5/19/2025

    Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company has entered into a Research Agreement on 13th August, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai").

  7. PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform For Novel Phenethylamines 5/15/2025

    PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and subsequent development.

  8. STEERLife Redefines Potent Drug Development With Clean, Green, Continuous Processing 5/15/2025

    STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science.

  9. Viva Biotech Launches The AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery 5/15/2025

    On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive AI-Driven Drug Discovery (AIDD) platform.

  10. Clarivate Enhances OFF-X With Pathway Maps To Accelerate Target Safety Assessments 5/14/2025

    Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution.